Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HOTH
stocks logo

HOTH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Hoth Therapeutics Inc (HOTH.O) is -2.27, compared to its 5-year average forward P/E of -1.61. For a more detailed relative valuation and DCF analysis to assess Hoth Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.61
Current PE
-2.27
Overvalued PE
-0.70
Undervalued PE
-2.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.16
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.18
Undervalued EV/EBITDA
-3.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

HOTH News & Events

Events Timeline

(ET)
2025-11-20
08:17:13
Hoth Therapeutics Joins Nvidia Connect Program
select
2025-10-21 (ET)
2025-10-21
08:26:53
Hoth Therapeutics' HT-KIT Receives Orphan Drug Designation from FDA
select
2025-10-08 (ET)
2025-10-08
08:04:52
Hoth Therapeutics Chooses Nvidia's AI Enterprise Platform
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-04PRnewswire
Hoth Therapeutics Advances Multiple Therapeutic Pipelines, Plans HT-KIT IND Submission in 2026
  • HT-001 Clinical Progress: Hoth Therapeutics is advancing its HT-001 in the CLEER-001 clinical trial targeting EGFR inhibitor-associated rash, a significant unmet need in oncology supportive care, with further clinical updates expected in the coming months.
  • HT-KIT IND Preparation: Hoth's HT-KIT program for mast cell diseases is progressing through IND-enabling activities, with IND submission expected in 2026, marking a significant step in the company's efforts in the rare disease space.
  • HT-ALZ Development Progress: HT-ALZ continues to deliver supportive data across absorption, distribution, and neuroinflammatory pathways, showcasing its potential in Alzheimer's disease treatment and reinforcing the company's R&D foundation.
  • Accelerated GDNF Program: Hoth's new GDNF-based metabolic program targets obesity and metabolic dysfunction, representing one of the fastest-growing therapeutic markets globally, highlighting the company's strategic positioning to address major public health challenges.
[object Object]
Preview
3.5
12-04Newsfilter
Hoth Therapeutics Advances Multiple Clinical Programs, IND Submission Expected in 2026
  • HT-001 Clinical Progress: Hoth Therapeutics has made significant advancements in its Phase 2 CLEER-001 clinical trial for HT-001, demonstrating a strong safety profile with no dose-limiting toxicities observed, which is expected to enhance its competitive position in oncology supportive care.
  • HT-KIT Drug Development: The HT-KIT program targeting mast cell diseases has received FDA Orphan Drug Designation, with IND submission preparations underway and expected to be finalized in 2026, marking a strategic move into the rare disease sector.
  • HT-ALZ Research Advancement: The HT-ALZ program for Alzheimer's disease is progressing through GLP and PK development, with positive pharmacokinetic data expected to support future regulatory submissions, anticipated to mature in 2026.
  • New GDNF Program Launch: Hoth's new GDNF-based metabolic program has initiated collaboration with the Atlanta VA Medical Center to target obesity and metabolic dysfunction, aiming to enter one of the fastest-growing therapeutic markets, with early data expected in 2026.
[object Object]
Preview
1.0
12-01PRnewswire
Hoth Therapeutics CEO Robb Knie to Present at NobleCon Conference
  • Conference Appearance: Hoth Therapeutics CEO Robb Knie is scheduled to present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference in Boca Raton, FL on December 1, 2025, showcasing the company's innovations in the biopharmaceutical sector.
  • Company Positioning: Hoth Therapeutics focuses on developing innovative and impactful treatments aimed at improving patient quality of life, indicating its significant role in the clinical-stage biopharmaceutical market.
  • R&D Strategy: The company catalyzes the progression of drugs from the lab to clinical testing through collaborations with scientists, clinicians, and key opinion leaders, highlighting its pivotal role in early-stage pharmaceutical research and development.
  • Forward-Looking Statements: Hoth outlines its future business strategies and clinical trial timelines, acknowledging substantial market risks and uncertainties while expressing strong expectations for new products and market opportunities.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Hoth Therapeutics Inc (HOTH) stock price today?

The current price of HOTH is 1.19 USD — it has decreased -0.83 % in the last trading day.

arrow icon

What is Hoth Therapeutics Inc (HOTH)'s business?

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).

arrow icon

What is the price predicton of HOTH Stock?

Wall Street analysts forecast HOTH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOTH is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Hoth Therapeutics Inc (HOTH)'s revenue for the last quarter?

Hoth Therapeutics Inc revenue for the last quarter amounts to -4.08M USD, increased 83.05 % YoY.

arrow icon

What is Hoth Therapeutics Inc (HOTH)'s earnings per share (EPS) for the last quarter?

Hoth Therapeutics Inc. EPS for the last quarter amounts to -2792672.00 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Hoth Therapeutics Inc (HOTH)'s fundamentals?

The market is revising No Change the revenue expectations for Hoth Therapeutics, Inc. (HOTH) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -10.53%.
arrow icon

How many employees does Hoth Therapeutics Inc (HOTH). have?

Hoth Therapeutics Inc (HOTH) has 2 emplpoyees as of December 05 2025.

arrow icon

What is Hoth Therapeutics Inc (HOTH) market cap?

Today HOTH has the market capitalization of 18.46M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free